Laminin 111 E8

Demande de produit

Laminin 111 E8Contexte de la molécule

Laminin 111 is an extracellular matrix protein that has also been promoted for its ability to improve muscle regeneration and stabilize the plasma membrane in multiple forms of muscular dystrophy. Laminin 111 E8 is composed of the C-terminal end of Laminin alpha1, beta 1 and gamma 1 chains.

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
KN-057	KN-057; KN057	Phase 3 Clinical	Suzhou Alphamab Co Ltd	Hemophilia A; Hemophilia B	Details
MG-1113	MG-1113	Phase 1 Clinical	GC Biopharma Corp	Hemophilia A	Details
AP-017	AP017; AP-017	Phase 1 Clinical	Anyuan Pharmaceutical Technology (Shanghai) Co Ltd	Hemophilia A; Hemophilia B	Details

Informations sur les médicaments commercialisés

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Plus ancien nom de marque	Pays d'approbation le plus ancien	Indication la plus ancienne	Société d'approbation la plus ancienne	Date d'approbation la plus ancienne	Indication	Essai clinique
Concizumab	mAbTFPI2021; NN-7415; NNC-0172-0000-2021; Anti-TFPI; mAb-2021; NNC-0172-2021; NNC-172-2021	Approved	Novo Nordisk A/S	Alhemo	Canada	Hemophilia B	Novo Nordisk Canada Inc	2023-04-17	Hemophilia A; Hemophilia B; Hemorrhage	Details
Marstacimab	PF-6741086; PF-06741086	Approved	Pfizer Inc	HYMPAVZI	United States	Hemophilia A; Hemophilia B	Pfizer Inc	2024-10-11	Hemophilia A; Hemophilia B; Hemorrhage	Details